Company Filing History:
1 out of 3 
1 out of 13 Years Active: 2016
Title: Innovator in Neuropsychiatric Research: Jose Javier Meana
Introduction: Jose Javier Meana is a prominent inventor based in Bizkaia, Spain. His innovative work focuses on the intersection of transgenic technology and neuropsychiatric research. He has significantly contributed to the understanding and treatment of neuropsychiatric illnesses through his unique inventions.
Latest Patents: Jose Javier Meana holds a patent titled "STXBP1 Overexpressing Mouse and Its Uses in Screening of Treatments for Neuropsychiatric Illness." This groundbreaking patent involves a non-human transgenic animal containing a polynucleotide that encodes an STXBP1 polypeptide. The invention is designed to enhance the expression of the STXBP1 polypeptide in at least one brain region, outperforming wild-type expression levels. The patent outlines related vectors, methods for producing transgenic animals, in vitro and in vivo screening methods for potential therapeutic agents, as well as methods for diagnosing and treating neuropsychiatric illnesses.
Career Highlights: Throughout his career, Jose has made substantial strides in the field of biopharmaceuticals. He has been affiliated with Brainco Biopharma, where his expertise has contributed to advancements in neuropsychiatric treatment methodologies. Additionally, he has worked with the Universidad Del País Vasco (Euskal Herriko Unibertsitatea), leveraging academic research to drive innovation in the healthcare sector.
Collaborations: Jose Javier Meana has collaborated with notable professionals in his field, including Maria Jose Guerrero Martinez and Laureano Simon Buela. These partnerships have fostered a collaborative environment that enhances research outcomes and the potential for groundbreaking discoveries in neuropsychiatric therapies.
Conclusion: Jose Javier Meana stands out as a significant figure in the realm of neuropsychiatric innovations. His patent on the STXBP1 overexpressing mouse exemplifies his commitment to developing tools that can aid in the treatment of psychiatric disorders. Through his collaborations with companies and universities, he continues to push the boundaries of neurobiological research, paving the way for future advancements in mental health treatment.